The Trump administration has struck a deal with Eli Lilly and Novo Nordisk to lower the costs of GLP-1 weight loss drugs and expand access for Medicare recipients. While the agreement promises to save the government money and increase prescriptions, specific details regarding pricing structures and policy mechanisms remain unclear. The arrangement raises significant questions about the economic impact on the pharmaceutical giants and the broader public health implications of wider availability.